Ardelyx, Inc., a biopharmaceutical company, has filed a new Form S-8 registration statement with the Securities and Exchange Commission (SEC) on February 27, 2024. This filing pertains to the registration of additional shares for the company's equity incentive plans. Specifically, Ardelyx is registering an additional 9,298,127 shares of common stock under its 2014 Equity Incentive Award Plan and 5,750,000 shares under its 2016 Employment Commencement Incentive Plan. These shares are now available for grant following the automatic annual increase provisions and the action of the Board of Directors on January 16, 2024. The registration statement incorporates by reference several previous filings, including the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The new shares are intended for issuance as awards under the plans are exercised and/or vest, with the aim to incentivize and retain employees.

Ardelyx, Inc., a biopharmaceutical company, has filed a new Form S-8 registration statement with the Securities and Exchange Commission (SEC) on February 27, 2024. This filing pertains to the registration of additional shares for the company's equity incentive plans. Specifically, Ardelyx is registering an additional 9,298,127 shares of common stock under its 2014 Equity Incentive Award Plan and 5,750,000 shares under its 2016 Employment Commencement Incentive Plan. These shares are now available for grant following the automatic annual increase provisions and the action of the Board of Directors on January 16, 2024. The registration statement incorporates by reference several previous filings, including the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2023. The new shares are intended for issuance as awards under the plans are exercised and/or vest, with the aim to incentivize and retain employees.